false 0001157075 0001157075 2023-11-20 2023-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 20, 2023

 

PHARMACYTE BIOTECH, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Nevada 001-40699 62-1772151
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

 

3960 Howard Hughes Parkway, Suite 500
Las Vegas, Nevada		 89169
(Address of Principal Executive Offices) (Zip Code)
   

 

Registrant's telephone number, including area code: (917) 595-2850

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, Par Value $0.0001 Per Share   PMCB  

The Nasdaq Stock Market LLC

         

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

   

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On November 20, 2023 (the “Grant Date”), the board of directors (the “Board”) of PharmaCyte Biotech, Inc. (the “Company”) approved a one-time grant (the “Silverman Grant”) to Joshua N. Silverman, Interim Chief Executive Officer and Interim President of the Company, consisting of (i) $100,000 in cash and (ii) options to purchase up to 170,000 shares of the Company’s common stock at an exercise price of $2.18 per share. The options vest 50% on the Grant Date and 50% on the one-year anniversary of the Grant Date. The Silverman Grant was made pursuant to the PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan (the “Plan”).

 

Also on the Grant Date, the Board approved a one-time grant (the “Trujillo Grant”) to Carlos A. Trujillo, Chief Financial Officer of the Company, consisting of (i) $50,000 in cash and (ii) options to purchase up to 85,000 shares of the Company’s common stock at an exercise price of $2.18 per share. The options vest 50% on the Grant Date and 50% on the one-year anniversary of the Grant Date. The Trujillo Grant was made pursuant to the Plan.

 

 

 

 3 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 24, 2023 PHARMACYTE BIOTECH, INC.
     
     
  By:

/s/ Joshua N. Silverman                                           

  Name: Joshua N. Silverman
  Title: Interim Chief Executive Officer and Interim President

 

 

 

 

 

 

 

 

 

 

 

 

 

 4 
v3.23.3
Cover
Nov. 20, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 20, 2023
Entity File Number 001-40699
Entity Registrant Name PHARMACYTE BIOTECH, INC.
Entity Central Index Key 0001157075
Entity Tax Identification Number 62-1772151
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 3960 Howard Hughes Parkway
Entity Address, Address Line Two Suite 500
Entity Address, City or Town Las Vegas
Entity Address, State or Province NV
Entity Address, Postal Zip Code 89169
City Area Code (917)
Local Phone Number 595-2850
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol PMCB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Dec 2024 to Dec 2024 Click Here for more PharmaCyte Biotech Charts.
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more PharmaCyte Biotech Charts.